ArticleFrontiers in immunology2025
Sex-specific and socioeconomic disparities in the global burden of inflammatory bowel disease in 204 countries, 1990-2021: projections to 2050.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory bowel disease (IBD) represents a growing global health challenge, necessitating a systematic evaluation of its epidemiological trends and sociodemographic disparities. Methods: Using Global Burden of Disease 2021 data, we quantified IBD burden (incidence, mortality, prevalence, disability-adjusted life years [DALYs], years lived with disability [YLDs], and years of life lost [YLLs]) across 204 countries and territories from 1990 to 2021, and projected trends to 2050, evaluating associations with Sociodemographic Index (SDI) and sex disparities. Results: Between 1990 and 2021, global crude counts of incident cases, deaths, prevalence, DALYs, YLDs, YLLs increased by 88.3%, 98.1%, 76.5%, 59.2%, 75.1%, and 50.8%, respectively. However, age-standardized rates (ASRs) of mortality, prevalence, DALYs, YLDs, and YLLs declined by 13.0%, 6.5%, 16.1%, 6.6%, and 21.0%, respectively, contrasting with a modest rise in age-standardized incidence rates (ASIR, 5.5%). The average annual percentage changes (AAPCs) of Incidence, Mortality, Prevalence, DALYs, YLDs, and YLLs were 0.1582, -0.4885, -0.2223, -0.5704, -0.2237, -0.7686, respectively. Projections to 2050 indicate continued reductions in ASRs across all metrics. High and middle-high SDI regions retained the highest absolute burdens, yet low to middle-SDI regions exhibited the steepest escalation in crude incidence and prevalence, correlating strongly with rising SDI (Spearman's ρ=0.599 for incidence). Females showed a bimodal pattern, with higher disability and prevalence in both mid-life and very old age groups. Conclusions: High-SDI regions remain IBD epicenters, but accelerating burdens in low- and middle-SDI areas demand context-specific interventions. Persistent sex/age disparities necessitate tailored healthcare strategies to address the evolving global burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.